| Cancer testis antigen expression across T‐cell lymphoma subtypes. H Ma, CR Soderquist, E Marchi, L Scotto, G Bhagat, OA O'Connor Hematological Oncology 38 (5), 2020 | 1 | 2020 |
| Generation of pralatrexate resistant T‐cell lymphoma lines reveals two patterns of acquired drug resistance that is overcome with epigenetic modifiers L Scotto, C Kinahan, B Casadei, M Mangone, E Douglass, VV Murty, ... Genes, Chromosomes and Cancer 59 (11), 639-651, 2020 | 1 | 2020 |
| Prolonged progression free survival in a subset of responders to the combination of brentuximab vedotin and bendamustine in heavily treated patients with relapsed or refractory … A Sawas, H Ma, J Kuruvilla, JK Lue, C Deng, E Marchi, F Montanari, ... Leukemia & Lymphoma 61 (12), 3014-3017, 2020 | 2 | 2020 |
| The peripheral T-cell lymphomas: an unusual path to cure H Ma, E Marchi, OA O'Connor The Lancet Haematology 7 (10), e765-e771, 2020 | 20 | 2020 |
| Low dose continuous lenalidomide in heavily pretreated patients with relapsed or refractory classical Hodgkin lymphoma: a retrospective case series H Ma, B Cheng, F Montanari, JK Lue, C Deng, E Marchi, OA O’Connor, ... Therapeutic Advances in Hematology 11, 2040620720947340, 2020 | 2 | 2020 |
| Abstract CT160: The integration of PD1 blockade with epigenetic therapy is highly active and safe in heavily treated patients with T-cell lymphoma E Marchi, H Ma, F Montanari, A Sawas, JK Lue, C Deng, KT Whitfield, ... Cancer Research 80 (16_Supplement), CT160-CT160, 2020 | 2 | 2020 |
| Characterizing the belinostat response in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma A Sawas, H Ma, A Shustov, P Hsu, G Bhat, M Acosta, S Horwitz, ... Leukemia & lymphoma 61 (8), 2003-2007, 2020 | 5 | 2020 |
| The Integration of PD1 blockade with epigenetic therapy is highly active and safe in heavily treated patients with T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL). E Marchi, H Ma, F Montanari, A Sawas, JK Lue, C Deng, KT Whitfield, ... Journal of Clinical Oncology 38 (15_suppl), 8049-8049, 2020 | 6 | 2020 |
| A survey of cancer testis antigen (CTA) expression across T-cell lymphoma subtypes. H Ma, CR Soderquist, E Marchi, L Scotto, G Bhagat, OA O'Connor Journal of Clinical Oncology 38 (15_suppl), e15246-e15246, 2020 | | 2020 |
| Survival benefit in patients with peripheral T‐cell lymphomas after treatments with novel therapies and clinical trials H Ma, B Cheng, L Falchi, E Marchi, A Sawas, G Bhagat, OA O'Connor Hematological Oncology 38 (1), 51-58, 2020 | 27 | 2020 |
| Outcomes in patients with aggressive B‐cell non‐Hodgkin lymphoma after intensive frontline treatment failure EC Ayers, S Li, LJ Medeiros, DA Bond, KJ Maddocks, P Torka, ... Cancer 126 (2), 293-303, 2020 | 32 | 2020 |
| Novel Drugs and Clinical Trial-Based Treatments Prolong Survival of Peripheral T-Cell Lymphomas (PTCL) Patients: Single Institution Retrospective Analysis H Ma, E Marchi, B Cheng, G Bhagat, OA O'Connor Blood 134, 3486, 2019 | | 2019 |
| Belinostat induces high overall response rate (ORR) in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma (AITL) A Sawas, H Ma, A Shustov, P Hsu, G Bhat, M Acosta, SM Horwitz, ... Blood 134, 4050, 2019 | 4 | 2019 |
| A peripheral T-cell lymphoma (PTCL) arising as a post-transplant lymphoproliferative disorder: efficacy of pralatrexate in primary refractory disease and review of the literature H Ma, G Bhagat, OA O'Connor Leukemia & Lymphoma, 2019 | 2 | 2019 |
| Survival outcomes of patients with peripheral T-cell lymphomas (PTCL) treated with chemotherapy and/or novel agents: The Columbia University experience. H Ma, B Cheng, OA O'Connor Journal of Clinical Oncology 37 (15_suppl), e19049-e19049, 2019 | 2 | 2019 |
| New directions in treating peripheral T-cell lymphomas (PTCL): leveraging epigenetic modifiers alone and in combination H Ma, OA O’Connor, E Marchi Expert Review of Hematology 12 (3), 137-146, 2019 | 14 | 2019 |
| Combining biology and chemistry for a new take on chemotherapy: antibody-drug conjugates in hematologic malignancies H Ma, A Sawas Current Hematologic Malignancy Reports 13, 555-569, 2018 | 6 | 2018 |
| Outcome of Patients with Aggressive B Cell Lymphomas Who Receive Second-Line Salvage Immunochemotherapy Following Treatment Failure of Intensive First-Line Immunochemotherapy EC Ayers, S Li, J Medeiros, DA Bond, KJ Maddocks, P Torka, AM Hicks, ... Blood 132, 453, 2018 | 1 | 2018 |
| A web-based multimedia program before colonoscopy increased knowledge and decreased anxiety, sedation requirement, and procedure time S Parker, J Zipursky, H Ma, GL Baumblatt, CA Siegel Journal of clinical gastroenterology 52 (6), 519-523, 2018 | 31 | 2018 |
| The future of combination therapies for peripheral T cell lymphoma (PTCL) H Ma, A Davarifar, JE Amengual Current hematologic malignancy reports 13, 13-24, 2018 | 25 | 2018 |
